5. REFERENCES

1. US National Institute of drugs, (2009), Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions, Clinical trials.gov,13th May.
2. Ritesh Singla, Vippan Goyal, Gaurav Singla, Pooja Gupta, Rajiv kumar, (2011), Acute Ocular Side Effects of Topiramate, Journal of Clinical and Diagnostic Research, October, Vol-5(5): 1082-1085.
3. US National Institute of drugs, (2011), Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions, Clinical trials.gov, September 8,
4. Luca Spaccapelo, Silvia Leschiutta, Claudio Aurea1 and Anna Ferrari, (2009), Topiramate-associated acute glaucoma in a migraine patient receiving concomitant citalopram therapy: a case-Journal report, 26 January
5. US National Institute of drugs, (2011), Topiramate Bioequivalence Study Brazil – Fast. Clinical trials.gov , September 21,
6. Ipharma SA de CV, Monterrey, México, Bioequilvalencia @i-pharma.com.mx, PMID: 19302913, [PubMed - indexed for MEDLINE]
7. MEDICATION GUIDE, (2011), TOPAMAX® (TOE-PA-MAX) (topiramate) Tablets and Sprinkle Capsules , FDA Approved Labeling Text dated July 15, NDA 020505/S-042 & NDA 020844/S-036,
8. Guerrini R, Parmeggiani L, (2006), “Topiramate and its clinical applications in epilepsy”, Expert Opin Pharmacother ;7: pp. 811–823.
9. Saavedra I, Tamayo E, Gamboa A, Sasso J, Varela N, Moreno I, Marchant D, Cáceres D, Quiñones L., PMID: 20420791,[PubMed - indexed for MEDLINE]
10. Jin-Hee Park, Yoo-Sin Park, Min-Ho Lee, Si-Youn Rhim, Jae-Chul Song, (2008), Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers, Biomedical chromatography BMC ,Volume: 22, Issue: 8, Pages: 822-829.
11. A.R. Towne, MD; L.K. Garnett, RN, MSHA; E.J. Waterhouse, MD; L.D. Morton, MD; and R.J. DeLorenzo, MD, PhD, MPH, Towne AR, Pellock JM, Ko D, Determinants of mortality in status epilepticus. Epilepsia 1994;35:27–34.
12. ALI MOHAMMADI, NASRIN REZANOUR, MAHDI ANSARI§ and RODERICK B. WALKER, (2010), *Department of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Grahamstown-6140, South Africa,* Asian Journal of Chemistry Vol. 22, No. 5 ,3856-3866.
13. Gh. Bahrami, Sh. Mirzaeei, A. Kiani, (2004), Medical Biology Research Center, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran, online 5 November .
14. Sandra D Gawley, (2009), Topiramate induced acute transient myopia: a case report, *Cases Journal* , 2:7430 doi:10.4076/1757-1626-2-7430.

15. US National Institute of drugs, (2008), Applesauce Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg, Clinical trials.gov , March 30,
16. William E Rosenfeld, MD , Dennis R Doose, Sally A Walker, James S Baldassarre, Ross A Reife, (1999), A study of topiramate pharmacokinetics and tolerability in children with epilepsy, Pediatric Neurology ,Volume 20, Issue 5, May, Pages 339–344
17. Teva Pharmaceuticals USA (2009), August 14,
18. Pharmacokinetic Interactions of Topiramate, (2004), Volume 43 - Issue 12
19. Rx drug information, pharmaceutical research, Controlled-Release Phentermine /Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). [2011.11.03],Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. [2011.10.19]
20. Pill Identifier Search, (2011), February 11,
21. Suhas Sahebrao Khandave*, Shahoo Vasant Onkar, Satish Vitthal Sawant and Santosh Shrikrishna Joshi, (2010), Evaluation of Performance of the Truncated Area Under Curve (AUC) as a Primary Pharmacokinetic Parameter in Bioequivalence Studies, Journal of Bioequivalence & Bioavailability, Volume 2(4): 077-080 .
22. MHRA, UKPAR Topiramate 25, 50, 100, 200mg Film-Coated Tablets PL24668/0007-14, (2008), 13th March,
23. Draft Guidance on Topiramate, Analytes to measure (in appropriate biological fluid): Topiramate in plasma, Recommended May 2005, Revised Jul 2009.
24. Delbelo MP, Findling RL, Khusner S,Wang D (2005) , A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder, Controlled Clinical Trial, Journal Article, Multicenter Study. 44(6):539-547
25. Emma Varkey, Asa Cider, Jane Carlsson and Mattias Linde (2011), Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls, International Headache Society, Cephalalgia 31(14).
26. Shang-Peng Wu,Jing-Jane Tsai & Po-Wu Gean (1998), Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices, British Journal of Pharmacology, 125, 826 ± 832.
27. Tobias Leniger, Jan Tho¨ ne & Martin Wiemann (2004), Topiramate modulates pH of hippocampal CA3 neurons by combined effects on carbonic anhydrase and Cl_/HCO3_ exchange., British Journal of Pharmacology, 142, 831–842.
28. Yasser Khazaal and Daniele Fabio Zullino (2006), Topiramate in the treatment of compulsive sexual behavior: case report, BMC Psychiatry , **6**:22

29. Diana Ferraro, Girolamo Di Trapani (2008), Topiramate in the prevention of pediatric migraine: literature review, J Headache Pain 9:147–150.
30. Y. L. Lo • S. Y. Lum • S. Fook-Chong •H. C. Siow (2010),. A pilot study of topiramate dosages for migraine prophylaxis in an Asian population, J Headache Pain ,11:175–178.
31. Frank Ritter, *Tracy **A.** Glauser, +Roy D. Elterman, $Elaine Wyllie, and the Topiramate YP Study Group* (2000) ,Effectiveness, Tolerability, and Safety of Topiramate in Children with Partial-Onset Seizures, Epilepspsia, 41(Suppl. l):S82-S85
32. Martin Holtkamp, Florian Weissinger, and Hartmut Meierkord (2005),Erectile Dysfunction with Topiramate Epilepsia, Vol. 46, No. 1.
33. Stephen D. Silberstein, MD; Richard B. Lipton, MD; DavidW. Dodick, MD; Frederick G. Freitag, DO; Nabih Ramadan, MD; Ninan Mathew, MD; Jan L. Brandes, MD; Marcelo Bigal, MD; Joel Saper, MD; Steven Ascher, PhD; Donna M. Jordan, RN; Steven J. Greenberg, MD; Joseph Hulihan (2007), Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial, American Headache Society, 47:170-180
34. Marie-Aude Rigoulot, Any Boehrer, and Astrid Nehlig, (2003), Effects of Topiramate in Two Models of Genetically Determined Generalized Epilepsy, the GAERS and the Audiogenic Wistar AS, Epilepsia, 44(1):14–19.
35. Graeme J. Sills, Elaine Butler, Gerard Forrest, Neville Ratnaraj, Philip N. Patsalos,and Martin J. Brodie (2003), Vigabatrin, but not Gabapentin or Topiramate, Produces Concentration-related Effects on Enzymes and Intermediates of the GABA Shunt in Rat Brain and Retina, Epilepsia, 44(7):886–892,
36. M. Scott Perry, Philip J. Holt, and John T. Sladky (2006), Topiramate Loading for Refractory Status Epilepticus in Children, Epilepsia, Vol. 47, No. 6,
37. Pascual J, Rivas MT, Leira R. (2006), Testing the combination beta-blocker plus topiramate in refractory migraine, Acta Neurol Scand 2007: 115: 81–83
38. Jung-Mi Kim, Soonhak Kwon,Hye-Eun Seo, Byung Ho Choe, Min-Hyun Cho1, and Sung-Pa Park, (2009), Long-term Effectiveness and Tolerability of Topiramate in Children with Epilepsy under the Age of 2 Years: 4-Year Follow-up, J Korean Med Sci ; 24: 1078-82.
39. Marco Mula, Andrea E Cavanna, Francesco Monaco, (2006), Sychopharmacology of topiramate: from epilepsy to bipolar disorder, Neuropsychiatric Disease and Treatment :2(4) 475–488
40. Bankole A. Johnson, D.Sc., M.D., Ph.D.a,*, Lynda T. Wells, M.D.b, John D. Roache, Ph.D.c,Christopher L. Wallace, M.D.c, Nassima Ait-Daoud, M.D.a, Michael A. Dawes, M.D.d, Lei Liu, Ph.D.e, Xin-Qun Wang, M.S.e, and Martin A. Javors, Ph.D, (2007), kinetic and cardiovascular effects of acute Topiramate dosing among non-treatment seeking, methamphetamine-dependent individuals, Prog Neuropsychopharmacol Biol Psychiatry; 31(2): 455–461.
41. Susan L. McElroy, Trisha Suppes, Paul E. Keck, Jr., Mark A. Frye,Kirk D. Denicoff, Lori L. Altshuler, E. Sherwood Brown, Willem A. Nolen, Ralph W. Kupka, Jennifer Rochussen, Gabriele S. Leverich, and Robert M. Post, (2000), Open-Label Adjunctive Topiramate in the Treatment of Bipolar Disorders, Biol Psychiatry, 47:1025–1033.